Cochrane · systematic review · CD007026
Cerebrolysin for acute ischaemic stroke
Ziganshina, LE, Abakumova, T, Nurkhametova, D, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
4
No studies
3
Included studies
NR
No studies 3 · 42.9%Ungraded 0 · 0%Very low 1 · 14.3%Low 1 · 14.3%Moderate 2 · 28.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyCerebrolysin or Cerebrolysin‐like agents compared to placebo for acute ischaemic stroke
Population: people with acute ischaemic stroke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause death ( Cerebrolysin or Cerebrolysin‐like agents vs placebo | RR 0.96 [0.65, 1.41] | 6 studies · 1689 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Non‐death attrition Cerebrolysin or Cerebrolysin‐like agents vs placebo | RR 0.72 [0.38, 1.39] | 6 studies · 1689 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Total number of people with SAEs** Cerebrolysin or Cerebrolysin‐like agents vs placebo | RR 1.16 [0.81, 1.66] | 3 studies · 1335 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Total number of people with adverse events, Cerebrolysin or Cerebrolysin‐like agents vs placebo | RR 1.03 [0.92, 1.14] | 4 studies · 1607 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Death or dependence, Cerebrolysin or Cerebrolysin‐like agents vs placebo | no estimate extracted | NR | No studies |
Early death (within 2 weeks of stroke onset) Cerebrolysin or Cerebrolysin‐like agents vs placebo | no estimate extracted | NR | No studies |
Quality of life Cerebrolysin or Cerebrolysin‐like agents vs placebo | no estimate extracted | NR | No studies |
Cerebrolysin compared to placebo for acute ischaemic stroke
Population: people with acute ischaemic stroke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause death at the end of the Cerebrolysin vs placebo | RR 0.89 [0.6, 1.31] | 6 studies · 1517 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Total number of people with SAEs Cerebrolysin vs placebo | RR 1.15 [0.81, 1.65] | 4 studies · 1435 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Total number of people with adverse events at the end of the Cerebrolysin vs placebo | RR 1.01 [0.9, 1.12] | 4 studies · 1435 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Non‐death attrition Cerebrolysin vs placebo | RR 0.97 [0.45, 2.06] | 6 studies · 1517 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Death or dependence at the end of the Cerebrolysin vs placebo | no estimate extracted | 7 studies · 1601 participants | Ungraded |
Early death (within 2 weeks of stroke onset) Cerebrolysin vs placebo | no estimate extracted | 7 studies · 1601 participants | Ungraded |
Quality of life Cerebrolysin vs placebo | no estimate extracted | 7 studies · 1601 participants | Ungraded |
Cerebrolysin compared to placebo for acute ischaemic stroke
Population: people with acute ischaemic stroke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause death ‐ cerebrolysin dose 30 mL: 10 days; 10 mL: 10 days, 50 mL: 10 days, and cerebrolysin dose 50 mL: 21 days Cerebrolysin vs placebo | RR 0.91 [0.61, 1.35] | 5 studies · 1417 participants | Moderate Downgraded: risk of bias |
Total number of people with serious adverse events (SAEs) ‐ cerebrolysin dose 30 mL: 10 days and cerebrolysin dose 50 mL: 21 days Cerebrolysin vs placebo | RR 1.16 [0.81, 1.67] | 3 studies · 1335 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Total number of people with fatal SAEs ‐ cerebrolysin dose 30 mL: 10 days and cerebrolysin dose 50 mL: 21 days Cerebrolysin vs placebo | RR 0.9 [0.59, 1.38] | 3 studies · 1335 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Total number of people with non‐fatal SAEs ‐ cerebrolysin dose 30 mL: 10 days and cerebrolysin dose 50 mL: 21 days Cerebrolysin vs placebo | RR 2.47 [1.09, 5.58] | 3 studies · 1335 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Total number of people with adverse events ‐ cerebrolysin dose 30 mL: 10 days and cerebrolysin dose 50 mL: 21 days Cerebrolysin vs placebo | RR 0.97 [0.86, 1.09] | 3 studies · 1335 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Cerebrolysin compared to placebo for acute ischaemic stroke
Population: people with acute ischaemic stroke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause death Cerebrolysin vs placebo | RR 0.91 [0.61, 1.35] | 5 studies · 1417 participants | Moderate Downgraded: risk of bias |
Serious adverse events ‐ cerebrolysin dose 30 mL: 10 days Cerebrolysin vs placebo | RR 1.37 [1.01, 1.86] | 2 studies · 1189 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Total number of people with adverse events Cerebrolysin vs placebo | RR 0.97 [0.86, 1.09] | 3 studies · 1335 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Cerebrolysin versus placebo in people with acute ischaemic stroke
Population: people with acute ischaemic stroke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause death Cerebrolysin vs placebo | RR 0.87 [0.29, 2.58] | 1 study · 146 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Total number of adverse events Cerebrolysin vs placebo | RR 1.62 [0.69, 3.82] | 1 study · 146 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Death or dependence at the end of the Cerebrolysin vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Early death (within 2 weeks of stroke onset) Cerebrolysin vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |